Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 16 min 6 sec ago

Mazor Robotics Sells Second Renaissance System to Westside Surgical Hospital

Mon, 02/03/2014 - 13:57
CAESAREA, Israel--(Healthcare Sales & Marketing Network)--Mazor Robotics Ltd. (MZOR.TA) (NASDAQ GM: MZOR), a developer of innovative guidance systems and complementary products, announced today that it has sold a second Renaissance system to Westside Surgi...
Devices, Surgery
Mazor Robotics, Renaissance system, robotic surgery

Given Imaging Receives FDA Clearance for PillCam(R) COLON in Patients Following Incomplete Colonoscopy

Mon, 02/03/2014 - 13:48
PillCam COLON is the Only Non-Invasive and Radiation-Free Solution for the Approximately 750,000 Patients in the U.S. Who Experience an Incomplete Colonoscopy Each Year The Company's PillCam COLON Has a Global Market Opportunity of 3 Million Procedures ...
Devices, Gastroenterology, FDA
Given Imaging, PillCam COLON, capsule endoscopy

Mylan Launches First Trastuzumab Biosimilar, Hertraz(TM), in India

Mon, 02/03/2014 - 13:40
Availability of 150 mg formulation increases dosing convenience and flexibility MUMBAI and PITTSBURGH, Feb. 3, 2014 -- (Healthcare Sales & Marketing Network) -- Mylan Inc. (MYL), one of the world's leading generic and specialty pharmaceutical companies...
Biopharmaceuticals, Product Launch
Mylan, trastuzumab, Hertraz, biosimilar, breast cancer

Forest Laboratories, Inc. Files Lawsuit Against Several Companies for Infringement of NAMENDA XR(R) Patents

Sun, 02/02/2014 - 16:20
NEW YORK--(Healthcare Sales & Marketing Network)--Forest Laboratories, Inc. (FRX) and Forest Laboratories Holdings, Ltd. (collectively, “Forest”) announced that Forest, Merz Pharma GmbH & Co. KgaA (“Merz”) and Adamas Pharmaceuticals, Inc. (“Adamas”) have j...
Biopharmaceuticals, Neurology, Generics, Litigation
Forest Laboratories, Sun Pharma, Teva Pharmaceutical, NAMENDA XR

Eli Lilly and Company Provides Statement in Response to Sanofi U.S. Lawsuit

Fri, 01/31/2014 - 17:14
INDIANAPOLIS, Jan. 31, 2014 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (LLY) has provided the following statement regarding a lawsuit filed by Sanofi in the United States District Court for the District of Delaware alleging patent ...
Biopharmaceuticals, Endocrinology, Litigation
Eli Lilly, Sanofi, LY2963016, insulin glargine, diabetes

B. Braun Receives FDA Approval For Next Generation 1L Intravenous Containers

Fri, 01/31/2014 - 15:20
E3™ -The latest advancement in IV container technology in more than 25 years BETHLEHEM, Pa., Jan. 31, 2014 -- (Healthcare Sales & Marketing Network) -- B. Braun Medical Inc. (B.Braun), a leader in infusion therapy and pain management, announced today t...
Devices, Drug Delivery, FDA
B. Braun, E3 IV container

Acella Pharmaceuticals, LLC, Announces Approval and Launch of Loutrex Topical Cream

Fri, 01/31/2014 - 15:01
ATLANTA, Jan. 31, 2014 -- (Healthcare Sales & Marketing Network) -- Acella Pharmaceuticals, LLC, a specialty pharmaceutical company, recently announced the approval and launch of Loutrex Topical Cream following a successful 510(k)1 notification with the F...
Biopharmaceuticals, Devices, Dermatology, FDA
Acella Pharmaceuticals, Loutrex, seborrhea, dermatitis

Valeant Pharmaceuticals Announces Approval of Retin-A Micro(R) Microsphere 0.08%

Fri, 01/31/2014 - 14:56
LAVAL, Quebec , Jan. 31, 2014 (Healthcare Sales & Marketing Network) - Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has received approval from the Food and Drug Administration (FDA) for its Supplemental New ...
Biopharmaceuticals, Dermatology, FDA
Valeant Pharmaceuticals, Retin-A Micro, tretinoin, acne vulgaris

Actavis Announces Refocused Global Business Structure to Maximize Evolution into Global Specialty Pharmaceuticals Leadership

Fri, 01/31/2014 - 13:02
Realigns Existing Executive Team Expertise Redefines Commercial Structure to Focus on Globalization of Integrated Specialty Pharmaceuticals Portfolio Enhances Efficiencies in Global R&D, Regulatory Affairs and Pharmacovigilance DUBLIN, Jan. 31, 20...
Biopharmaceuticals, Personnel
Actavis

ImmunoGen, Inc. Appoints Eric Guempel as Vice President of Product Strategy and Program Management

Fri, 01/31/2014 - 12:57
WALTHAM, Mass.--(Healthcare Sales & Marketing Network)--ImmunoGen, Inc. (IMGN), a biotechnology company that develops targeted anticancer therapies using its industry leading antibody-drug conjugate (ADC) technology, today announced the appointment of Eric...
Biopharmaceuticals, Oncology, Personnel
ImmunoGen, antibody-drug conjugate

Miraculins Executes Term Sheet to Appoint Cachet Pharmaceutical as Exclusive Distributor of the Scout DS(R) Diabetes Test in China

Fri, 01/31/2014 - 12:53
Final Agreement to Include Upfront/Milestone Payments, a $15 Million USD First Order, and Projected Minimum Orders Valued at $75 Million USD over course of 5-Year Term WINNIPEG, MANITOBA--(Healthcare Sales & Marketing Network) - Miraculins Inc. (TSX VEN...
Diagnostics, Endocrinology, Distribution
Miraculins, Cachet Pharmaceutical, Scout DS, Diabetes Screening Test

RaySearch Laboratories: First RayStation(R) Order in the United Kingdom

Fri, 01/31/2014 - 12:45
STOCKHOLM--(Healthcare Sales & Marketing Network)--RaySearch Laboratories AB (publ.) has been awarded a contract to supply its RayStation® treatment planning system (TPS) to Tayside Cancer Centre, Ninewells Hospital & Medical School in Dundee, UK. Nine...
Devices, Oncology
RaySearch Laboratories, RayStation, treatment planning system, radiotherapy

Mylan Named as Gilead's Exclusive Branded Medicines Business Partner for India

Fri, 01/31/2014 - 12:36
PITTSBURGH and MUMBAI, India, Jan. 31, 2014 -- (Healthcare Sales & Marketing Network) -- Mylan Inc. (MYL) today announced that its India-based subsidiary Mylan Pharmaceuticals Private Limited has been named Gilead Sciences, Inc.'s (GILD) exclusive branded...
Biopharmaceuticals, Distribution
Mylan, Gilead Sciences, Viread, Truvada, Stribild, AmBisome

IlluminOss Medical Announces Spanish and Israeli Launch of Photodynamic Bone Stabilization System (PBSS)

Thu, 01/30/2014 - 20:37
EAST PROVIDENCE, R.I.--(Healthcare Sales & Marketing Network)--IlluminOss Medical, a privately held, commercial stage medical device company pioneering the development of minimally invasive fracture fixation technologies, has launched its proprietary Photo...
Devices, Orthopaedic, Distribution
IlluminOss Medical, Photodynamic Bone Stabilization

Novo Nordisk Promotes Eddie Williams to Senior Vice President

Thu, 01/30/2014 - 20:34
PRINCETON, N.J., Jan. 30, 2014 -- (Healthcare Sales & Marketing Network) -- Novo Nordisk (NVO), a global healthcare company with 90 years of innovation and leadership in diabetes care, announced the promotion of Eddie Williams to senior vice president of ...
Biopharmaceuticals, Endocrinology, Personnel
Novo Nordisk, diabetes

Ulthera(R) System Receives Third FDA Clearance

Thu, 01/30/2014 - 14:01
Non-Invasive Ultherapy(R) Ultrasound Procedure Recognized for Imaging Capabilities MESA, AZ--(Healthcare Sales & Marketing Network) - Ulthera, Inc. -- a global medical device company focused on developing and commercializing technologies for aesthetic a...
Devices, Dermatology, FDA
Ulthera, Ultherapy

Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman

Thu, 01/30/2014 - 13:53
TORONTO, ONTARIO--(Healthcare Sales & Marketing Network) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, is pleased to announce that its Board of Directors has elected Dr...
Biopharmaceuticals, Oncology, Personnel
Stem Cell Therapeutics, SIRPaFc, CD200, stem cell

Chelsea Therapeutics Names Keith W. Schmidt Chief Commercial Officer

Thu, 01/30/2014 - 13:23
CHARLOTTE, N.C., Jan. 30, 2014 -- (Healthcare Sales & Marketing Network) -- Chelsea Therapeutics International, Ltd. (CHTP) today announced that Keith W. Schmidt has been named Chief Commercial Officer, effective January 28, 2014. Mr. Schmidt has served as...
Biopharmaceuticals, Neurology, Personnel
Chelsea Therapeutics, NORTHERA, droxidopa

Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia

Thu, 01/30/2014 - 12:16
Relationship Leverages UCB’s Expertise and Presence in Asia to Bring Biogen Idec’s Innovative Therapies to Patients in New Markets CAMBRIDGE, Mass. & BRUSSELS, Belgium--(Healthcare Sales & Marketing Network)-- Biogen Idec (BIIB) and UCB (Euronext:UCB) a...
Biopharmaceuticals, Licensing
Biogen Idec, UCB , multiple sclerosis, TECFIDERA, FAMPYRA

Progenics Pharmaceuticals Announces the Appointment of Karen Ferrante, M.D. to Its Board of Directors

Wed, 01/29/2014 - 20:09
TARRYTOWN, N.Y., Jan. 29, 2014 -- (Healthcare Sales & Marketing Network) -- Progenics Pharmaceuticals, Inc. (PGNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced today that Karen Ferrant...
Biopharmaceuticals, Oncology, Personnel
Progenics Pharmaceuticals

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong